Literature DB >> 9619112

Niaziminin, a thiocarbamate from the leaves of Moringa oleifera, holds a strict structural requirement for inhibition of tumor-promoter-induced Epstein-Barr virus activation.

A Murakami1, Y Kitazono, S Jiwajinda, K Koshimizu, H Ohigashi.   

Abstract

Three known thiocarbamate (TC)- and isothiocyanate (ITC)-related compounds have been isolated from the leaves of Moringa oleifera, a traditional herb in southeast Asia, as inhibitors of tumor promoter teleocidin B-4-induced Epstein-Barr virus (EBV) activation in Raji cells. Interestingly, only niaziminin among 10 TCs including 8 synthetic ones showed considerable inhibition against EBV activation. The structure-activity relationships indicated that the presence of an acetoxy group at the 4'-position of niaziminin is important and indispensable for inhibition. On the other hand, among the ITC-related compounds, naturally occurring 4-[(4'-O-acetyl-alpha-L-rhamnosyloxy)benzyl]ITC and commercially available allyl- and benzyl-ITC significantly inhibited activation, suggesting that the isothiocyano group is a critical structural factor for activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9619112     DOI: 10.1055/s-2006-957442

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  25 in total

1.  Tissue-Specific Metabolic Profile Study of Moringa oleifera L. Using Nuclear Magnetic Resonance Spectroscopy.

Authors:  Iqbal Mahmud; Kamal Chowdhury; Arezue Boroujerdi
Journal:  Plant Tissue Cult Biotechnol       Date:  2014-06

Review 2.  Possible role of Moringa oleifera Lam. root in epithelial ovarian cancer.

Authors:  Chinmoy K Bose
Journal:  MedGenMed       Date:  2007-02-06

3.  New α-glucosides of caffeoyl quinic acid from the leaves of Moringa oleifera Lam.

Authors:  Yoshiki Kashiwada; Fakhruddin Ali Ahmed; Shin-ichiro Kurimoto; Sang-Yong Kim; Hirofumi Shibata; Toshihiro Fujioka; Yoshihisa Takaishi
Journal:  J Nat Med       Date:  2011-07-05       Impact factor: 2.343

4.  Protective effects of Moringa oleifera Lam. leaves against arsenic-induced toxicity in mice.

Authors:  Afzal Sheikh; Fouzia Yeasmin; Smita Agarwal; Mashiur Rahman; Khairul Islam; Ekhtear Hossain; Shakhawoat Hossain; Md Rezaul Karim; Farjana Nikkon; Zahangir Alam Saud; Khaled Hossain
Journal:  Asian Pac J Trop Biomed       Date:  2014-05

5.  A potential oral anticancer drug candidate, Moringa oleifera leaf extract, induces the apoptosis of human hepatocellular carcinoma cells.

Authors:  Il Lae Jung; Ju Hye Lee; Se Chan Kang
Journal:  Oncol Lett       Date:  2015-07-10       Impact factor: 2.967

6.  Extension of life span and stress tolerance modulated by DAF-16 in Caenorhabditis elegans under the treatment of Moringa oleifera extract.

Authors:  Anita Prabhatsinh Chauhan; Mukesh Ghanshyam Chaubey; Stuti Nareshkumar Patel; Datta Madamwar; Niraj Kumar Singh
Journal:  3 Biotech       Date:  2020-11-04       Impact factor: 2.406

7.  Bioenhancers from mother nature and their applicability in modern medicine.

Authors:  Gurpreet Kaur Randhawa; Jagdev Singh Kullar
Journal:  Int J Appl Basic Med Res       Date:  2011-01

8.  Experimental Assessment of Moringa oleifera Leaf and Fruit for Its Antistress, Antioxidant, and Scavenging Potential Using In Vitro and In Vivo Assays.

Authors:  Suaib Luqman; Suchita Srivastava; Ritesh Kumar; Anil Kumar Maurya; Debabrata Chanda
Journal:  Evid Based Complement Alternat Med       Date:  2011-12-14       Impact factor: 2.629

Review 9.  A Brief Overview of Potential Treatments for Viral Diseases Using Natural Plant Compounds: The Case of SARS-Cov.

Authors:  Rambod Abiri; Hazandy Abdul-Hamid; Oksana Sytar; Ramin Abiri; Eduardo Bezerra de Almeida; Surender K Sharma; Victor P Bulgakov; Randolph R J Arroo; Sonia Malik
Journal:  Molecules       Date:  2021-06-24       Impact factor: 4.411

10.  Inhibitory effects of crude extracts from some edible Thai plants against replication of hepatitis B virus and human liver cancer cells.

Authors:  Wanwisa Waiyaput; Sunchai Payungporn; Jiraphorn Issara-Amphorn; Nattanan T-Thienprasert Panjaworayan
Journal:  BMC Complement Altern Med       Date:  2012-12-06       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.